Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peters, W. P.
Right arrow Articles by Moore, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, W. P.
Right arrow Articles by Moore, J. O.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 6, 1368-1376, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

WP Peters, EJ Shpall, RB Jones, GA Olsen, RC Bast, JP Gockerman and JO Moore
Bone Marrow Transplant Program, Duke University Medical Center, Durham, NC 27710.

To evaluate the effect of high-dose chemotherapy in the treatment of metastatic breast cancer, we performed a phase II trial of a single treatment with high-dose cyclophosphamide (5,625 mg/m2), cisplatin (165 mg/m2), and carmustine (600 mg/m2), or melphalan (40 mg/m2) and bone marrow support as the initial chemotherapy for metastatic breast cancer. Twenty-two premenopausal patients with estrogen receptor negative, measurable metastatic disease were treated. Twelve of 22 patients (54%) obtained a complete response at a median 18 days. The overall response rate is 73% (complete and partial response). Median duration of response in the patients achieving complete response was 9.0 months with a median duration of survival for complete responders that is currently undefined. Relapse occurred predominantly at sites of pretreatment bulk disease or within areas of previous radiation therapy. Toxicity was frequent and five patients died of therapy- related complications. The results indicate that a single treatment with intensive combination alkylating agents with bone marrow support can produce more rapid and frequent complete responses than conventional chemotherapy when used as initial chemotherapy for metastatic breast cancer, although median disease-free and overall survival is not improved. Three patients (14%) remain in unmaintained remission beyond 16 months.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
N. Kroger, M. Frick, O. Gluz, S. Mohrmann, B. Metzner, C. Jackisch, Y. Ko, H.-W. Lindemann, C. R. Meier, H. P. Lohrmann, et al.
Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
J. Clin. Oncol., August 20, 2006; 24(24): 3919 - 3926.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
J. Clin. Oncol., July 1, 2006; 24(19): 3026 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
M. Mayer
Listen to all the voices: an advocate's perspective on early access to investigational therapies
Clinical Trials, April 1, 2006; 3(2): 149 - 153.
[Abstract] [PDF]

Home page
 Ann OncolHome page
R. C. Coombes, A. Howell, M. Emson, C. Peckitt, C. Gallagher, C. Bengala, A. Tres, R. Welch, P. Lawton, R. Rubens, et al.
High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial
Ann. Onc., May 1, 2005; 16(5): 726 - 734.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Takimoto and E. K. Rowinsky
Dose-Intense Paclitaxel: Deja Vu All Over Again?
J. Clin. Oncol., August 1, 2003; 21(15): 2810 - 2814.
[Full Text] [PDF]

Home page
 JCOHome page
M. Nottage and L. L. Siu
Principles of Clinical Trial Design
J. Clin. Oncol., September 15, 2002; 20(90001): 42s - 46.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Lillo, M. Ramirez, A. Alvarez, S. Santos, J. Garcia-Castro, J. Fernandez de Velasco, M. J. Aviles, A. Gomez-Pineda, J. L. Diez, A. Balas, et al.
Efficient and Nontoxic Adenoviral Purging Method for Autologous Transplantation in Breast Cancer Patients
Cancer Res., September 1, 2002; 62(17): 5013 - 5018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. B. Weiss, G. G. Gill, and C. A. Hudis
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
J. Clin. Oncol., June 1, 2001; 999(1): 1 - 8.
[Abstract] [Full Text]

Home page
 JCOHome page
R. B. Weiss, G. G. Gill, and C. A. Hudis
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
J. Clin. Oncol., June 1, 2001; 19(11): 2771 - 2777.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.A. Sosman, P. Stiff, S.M. Moss, P. Sorokin, B. Martone, R. Bayer, K. van Besien, S. Devine, W. Stock, D. Peace, et al.
Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post-Stem-Cell Infusion
J. Clin. Oncol., February 1, 2001; 19(3): 634 - 644.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Rodenhuis
The Status of High-Dose Chemotherapy in Breast Cancer
Oncologist, October 1, 2000; 5(5): 369 - 375.
[Abstract] [Full Text]

Home page
 JCOHome page
A. Patnaik, J. MacKinnon, P. Goss, T. Nagy, K. Stewart, A. Keating, and M. Crump
Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer
J. Clin. Oncol., June 12, 2000; 18(12): 2363 - 2368.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al.
Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer
N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes
High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer
Oncologist, February 1, 2000; 5(1): 1 - 13.
[Abstract] [Full Text]

Home page
 The OncologistHome page
R. B. Weiss
The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here?
Oncologist, December 1, 1999; 4(6): 450 - 458.
[Abstract] [Full Text]

Home page
 JAMAHome page
P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al.
Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
JAMA, October 13, 1999; 282(14): 1335 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Adkins, R. Brown, K. Trinkaus, R. Maziarz, S. Luedke, C. Freytes, B. Needles, D. Wienski, P. Fracasso, T. Pluard, et al.
Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 2006 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nieto, P. J. Cagnoni, E. J. Shpall, S. Matthes, A. Baron, R. B. Jones, and S. I. Bearman
Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease
Clin. Cancer Res., July 1, 1999; 5(7): 1731 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. L. Vogel and J.-M. Nabholtz
Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents
Oncologist, February 1, 1999; 4(1): 17 - 33.
[Abstract] [Full Text]

Home page
 The OncologistHome page
S. Subramanyan and M. J. Kennedy
Breast Cancer: High-Dose Therapy
Oncologist, October 1, 1998; 3(5): 289 - 299.
[Abstract] [Full Text]

Home page
 BloodHome page
E. J. Shpall, C. F. LeMaistre, K. Holland, E. Ball, R. B. Jones, R. Saral, C. Jacobs, S. Heimfeld, R. Berenson, and R. Champlin
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy
Blood, December 1, 1997; 90(11): 4313 - 4320.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Somlo, I. Sniecinski, T. Odom-Maryon, B. Nowicki, W. Chow, V. Hamasaki, L. Leong, K. Margolin, R. Morgan Jr, J. Raschko, et al.
Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer
Blood, March 1, 1997; 89(5): 1521 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. W. WILCZYNSKI, J. J. ERASMUS, W. P. PETROS, J. J. VREDENBURGH, and R. J. FOLZ
Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 565 - 573.
[Abstract] [Full Text]

Home page
 NEJMHome page
J. O. Armitage
Bone Marrow Transplantation
N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838.
[Full Text]

Home page
 NEJMHome page
M. S. Anscher, W. P. Peters, H. Reisenbichler, W. P. Petros, and R. L. Jirtle
Transforming Growth Factor {beta} as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer
N. Engl. J. Med., June 3, 1993; 328(22): 1592 - 1598.
[Abstract] [Full Text]

Home page
 JAMAHome page
B. E. Hillner, T. J. Smith, and C. E. Desch
Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results
JAMA, April 15, 1992; 267(15): 2055 - 2061.
[Abstract] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1988 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online